National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Durvalumab (Imfinzi®) for 1L extensive-stage small cell lung cancer. HTA ID 21033

Durvalumab  is indicated in combination with etoposide and either carboplatin or cisplatin, for the first-line treatment of adult patients with extensive-stage small cell lung cancer.

 

NCPE Assessment Process Complete
Rapid review commissioned 12/08/2021
Rapid review completed 09/09/2021
Rapid Review outcome A full HTA is not recommended. The NCPE recommends that durvalumab not be considered for reimbursement at the submitted price*

 

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.